Virat Crane Inds (519457)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 24.19% shows the business is expanding its topline.
• ROCE is positive at 9.30%, indicating some operating-level capital efficiency.
• Book value per share of ₹38.53 provides a tangible asset floor.
• Latest quarter sales of ₹48 Cr against a market cap of ₹158 Cr implies a modest sales multiple if growth sustains.

Concerns

• ROE is negative at -10.58%, and latest quarter net profit is -₹2 Cr on ₹48 Cr sales.
• Profit growth of -258.10% reflects severe earnings deterioration.
• P/B of 2.00 means the market demands a premium for a company destroying shareholder value.
• Piotroski F-Score of 4/9 and no dividend, with promoter holding undisclosed, raise governance and financial-health red flags.

AI Analysis

At first glance, a 24.19% sales growth rate catches my eye. But as a value investor, I buy businesses that generate growing earnings, not just growing sales. Virat Crane Inds, a dairy player, is doing the opposite. The latest quarter shows sales of ₹48 Cr but a net loss of ₹2 Cr, and full-year profit growth is -258.10%. ROE is deeply negative at -10.58%, meaning shareholder equity is being eroded rather than built. ROCE of 9.30% is positive but modest, and in a commodity-like dairy business without pricing power, that is not a durable moat. The balance sheet data is incomplete — Debt/Equity is N/A — so I cannot fully judge financial strength, and the Piotroski F-Score of 4/9 reinforces my caution. Valuation is the bigger problem. At ₹77.22, the stock trades at 2.00 times book value of ₹38.53, and the P/E is meaningless because earnings are negative. There is no dividend yield to compensate me for waiting. The stock is at the top of its 52-week range, but a rising price does not create intrinsic value; it only makes an already struggling company more expensive. In Graham's language, there is no margin of safety here. I would need to see a compelling path to positive earnings, better cost discipline, and proof that the 24% sales growth can translate into acceptable returns on equity. Until then, this is a speculative turnaround, not a compounding machine for my portfolio. I would rather watch from the sidelines than pay 2 times book for negative returns.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer